标题
FXR Agonists: From Bench to Bedside, a Guide for Clinicians
作者
关键词
Bile Acid, Portal Hypertension, NASH, Alcoholic Liver Disease, Nonalcoholic Fatty Liver Disease
出版物
DIGESTIVE DISEASES AND SCIENCES
Volume 61, Issue 12, Pages 3395-3404
出版商
Springer Nature
发表日期
2016-10-12
DOI
10.1007/s10620-016-4334-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Hepatic inflammation and fibrosis: Functional links and key pathways
- (2015) Ekihiro Seki et al. HEPATOLOGY
- P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis
- (2015) A. Pares et al. JOURNAL OF HEPATOLOGY
- LP15 : Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH)
- (2015) B. Hameed et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
- (2015) Jialin He et al. Molecular Cancer
- Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta – A study on maternal cholestasis model
- (2015) W.-B. Wu et al. PLACENTA
- Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis
- (2014) Weibin Wu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice
- (2014) F.A.R. Lívero et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation
- (2014) Chiara Degirolamo et al. HEPATOLOGY
- O15 EFFECTS OF THE FXR AGONIST OBETICHOLIC ACID ON HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN ALCOHOLIC CIRRHOSIS: A PROOF OF CONCEPT PHASE 2A STUDY
- (2014) R. Mookerjee et al. JOURNAL OF HEPATOLOGY
- FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation
- (2014) Jun Yao WORLD JOURNAL OF GASTROENTEROLOGY
- Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease
- (2013) Weibin Wu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
- (2013) Len Verbeke et al. HEPATOLOGY
- Positive regulation of osteogenesis by bile acid through FXR
- (2013) Sun Wook Cho et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
- (2013) Yongjie Ma et al. PHARMACEUTICAL RESEARCH
- Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
- (2012) Luciano Adorini et al. DRUG DISCOVERY TODAY
- Nuclear receptors in liver disease
- (2011) Martin Wagner et al. HEPATOLOGY
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- Farnesoid X Receptor Activation Improves Erectile Function in Animal Models of Metabolic Syndrome and Diabetes
- (2010) Linda Vignozzi et al. Journal of Sexual Medicine
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis
- (2009) A. Mencarelli et al. JOURNAL OF IMMUNOLOGY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
- (2009) Brenton Flatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Antiatherosclerotic effect of farnesoid X receptor
- (2008) Andrea Mencarelli et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now